This strategy allowed us to use Trastuzumab which is established clinically for the treatment of HER2-expressing breast cancer patients rather than working with an equivalent mouse HER2-specific antibody and mouse HER2-positive cancer cell lines. Here, ERBB2 is linked to cancer.